A significant new study from Finland has raised serious questions about the use of puberty blockers, cross-sex hormones, and surgeries for adolescents experiencing gender distress. For over a decade, proponents of these medical interventions have argued that they reliably improve mental health and can be life-saving for transgender-identified youth. However, this Finnish study, one of the largest and most methodologically rigorous to date, found no such benefit. Instead, it linked these treatments to a marked worsening of mental health outcomes.
Study Details and Findings
The research, published in Acta Paediatrica, utilized Finland's centralized health registries to analyze complete data for all 2,083 young people who presented to gender clinics before the age of 23 between 1996 and 2019. The study measured specialist-level psychiatric treatment both before referral to a gender clinic and two or more years afterward. Overall, gender-referred adolescents required significantly more psychiatric care than the general population at both time points. However, a closer examination of the numbers revealed alarming trends.
Comparison by Referral Period
The researchers divided patients into two groups based on referral period: 1996–2010 and 2011–2019. This distinction is crucial because the later period saw a sharp global rise in referrals to gender clinics, with caseloads surging and the sex ratio shifting from predominantly young boys to overwhelmingly adolescent girls. The study found that those referred after 2010 had significantly higher psychiatric needs overall. The authors concluded that for some young people, mental health challenges may manifest as concerns related to gender identity.
Impact of Medical Interventions
The study also compared those who received medical interventions (38.2% of the cohort) with those who did not. Among the non-medicalized group, psychiatric needs were high at referral—unsurprising given Finland's strict criteria that reserved treatment for the most stable adolescents—and showed little change at follow-up. In contrast, among the medicalized group—those selected because they initially presented with relatively stable mental health—specialist psychiatric care use rose sharply after commencing medical treatment. For males receiving feminizing treatment, psychiatric care use increased from roughly 10% to 61%, and for females receiving masculinizing treatment, it rose from 22% to 55%.
Implications for Canada
Canada has so far paid little attention to accumulating warnings from systematic evidence reviews and clinical course corrections abroad. Whether these latest findings will prompt Canadian gender clinics to reconsider their treatment approach remains an open question. The study adds to a growing body of evidence that medical transition fails to deliver promised mental health benefits and may even exacerbate psychiatric needs.
